Onsat4 mg

Ondansetron is a 5-HT3 receptor antagonist indicated for: Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. Prevention of nausea and vomiting associated with radiotherapy in patients receiving total body irradiation, single high-dose fraction to abdomen, or daily fractions to the abdomen. Prevention of postoperative nausea and/or vomiting.

Anti-emetic drugs

Ondansetron is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, ondansetron is not a dopamine-receptor antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals and centrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether ondansetron's antiemetic action is mediated centrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from the enterochromaffin cells of the small intestine.

The adult oral dosage is 24 mg given successively as three 8 mg films 30 minutes before the start of chemotherapy. Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy:Adults and pediatric patients 12 years of age and older: One 8 mg film 30 minutes before chemotherapy followed by an 8 mg dose 8 hours later. Administer one 8 mg film twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy. Pediatric patients 4 through 11 years of age: One 4 mg film three times a day. Administer the first dose 30 minutes before chemotherapy, with subsequent doses 4 and 8 hours later. Administer one 4 mg film three times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy. Prevention of nausea and vomiting associated with radiotherapy: The adult dosage is one 8 mg film three times a day.Postoperative nausea and vomiting: The adult dose is 16 mg given successively as two 8 mg films 1 hour before anesthesia.

Step 1: Tear the pouch carefully along with the edge tear mark.Step 2: Put the Ondansetron film on top of your tongue. It will dissolve within 20 seconds Step 3: Do not chew or swallow the film whole.Step 4: Swallow after the Onsaf oral soluble film dissolves. You may swallow the dissolved film with or without liquid.Step 5: Wash your hands after taking Onsaf oral soluble film

Apomorphine- profound hypotension and loss of consciousness.

Concomitant use of apomorphine. Hypersensitivity to ondansetron.

Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.The use of ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting

Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT3 receptor antagonists.The use of ondansetron in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting

Store at controlled room temperature 20° to 25°C. Store pouches in cartons. Keep product in pouch until ready to use.

Pediatrics: The safety and effectiveness in pediatric patients have only been established for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in patients four years of age and older.Impaired Hepatic Function: In severe hepatic impairment (Child-Pugh score of 10 or greater) 2, a total daily dose of 8 mg should not be exceeded.